Use

Kerecis to Provide Multiple Updates on its Medical-Fish-Skin Technology at the European Wound Management Association Meeting

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Surgery, Diabetes, Health, Medical Supplies, Use, Skin, Abstract, Excellence, Dicarboxylic acid, Cost, European Wound Management Association, Multimedia, Human, Complex, General surgery, EWMA, Fixation (psychology), NPWT, User experience, Dietary supplement

The company will also host a medical education event on the utilization of fish skin grafts on Wednesday, May 1.

Key Points: 
  • The company will also host a medical education event on the utilization of fish skin grafts on Wednesday, May 1.
  • Finally, Kerecis’ founder and CEO will summarize the company’s journey at the EWMA Innovation Forum Thursday, May 2.
  • Kerecis will be the subject of the following events at the conference:
    Intact Fish Skin for Chronic Wound Care – Dr. John Lantis, chair.
  • Thursday, May 2, 4 to 5 p.m. in the South Gallery Room 8-9-10
    Fish Skin for Wound Management: Are There Advantages?

Skyworks Reports Q2 FY24 Results

Retrieved on: 
Tuesday, April 30, 2024
Telecommunications, Hardware, Engineering, Consumer Electronics, Technology, IOT (Internet of Things), Semiconductor, Manufacturing, Use, Skyworks Solutions, EDT, Internet of things, AI, Traction, SWKS, Original equipment manufacturer, Oppo, CV2X, GAAP, Growth, Samsung, Mobile phone

Skyworks Solutions, Inc. (Nasdaq: SWKS), an innovator of high-performance analog and mixed-signal semiconductors connecting people, places and things, today reported second fiscal quarter results for the period ended March 29, 2024.

Key Points: 
  • Skyworks Solutions, Inc. (Nasdaq: SWKS), an innovator of high-performance analog and mixed-signal semiconductors connecting people, places and things, today reported second fiscal quarter results for the period ended March 29, 2024.
  • “Skyworks delivered solid results and strong cash generation in a challenging macroeconomic environment,” said Liam K. Griffin, chairman, chief executive officer and president of Skyworks.
  • Skyworks will host a conference call with analysts to discuss its second quarter fiscal 2024 results and business outlook on April 30, 2024, at 4:30 p.m. EDT.
  • Playback of the conference call will be available on Skyworks’ website at www.skyworksinc.com/investors beginning at 9 p.m. EDT on April 30, 2024.

Global Real-Time Payments Growth “Sustainable” As New Use Cases Push Transactions to Record Highs – ACI Worldwide Report

Retrieved on: 
Tuesday, April 30, 2024
Technology, Payments, Finance, Security, Fintech, Professional Services, Software, Data Analytics, Artificial Intelligence, Use, UPI, Nature, ACIW, Yoy, Partnership, Research, GlobalData, Synthetic media, QR, ACI Worldwide, Single Euro Payments Area, Multimedia, FedNow, Government, Friction, Growth, Online shopping

Global real-time payments growth has reached sustainable levels with 266.2 billion real-time payments transactions recorded in 2023—a year-over-year (YoY) growth of 42.2%—according to the 2024 Prime Time for Real-Time report, published by ACI Worldwide (NASDAQ: ACIW), a global leader in mission-critical, real-time payments software , in partnership with GlobalData , a leading data and analytics company.

Key Points: 
  • Global real-time payments growth has reached sustainable levels with 266.2 billion real-time payments transactions recorded in 2023—a year-over-year (YoY) growth of 42.2%—according to the 2024 Prime Time for Real-Time report, published by ACI Worldwide (NASDAQ: ACIW), a global leader in mission-critical, real-time payments software , in partnership with GlobalData , a leading data and analytics company.
  • India continues to dominate the global real-time payments market, with 129.3 billion transactions in 2023 – more than the rest of the world’s top 10 real-time payments markets combined.
  • Brazil saw a remarkable YoY growth of 77.9% in 2023, with 37.4 billion real-time payments transactions.
  • Asia Pacific (APAC) is the largest real-time payments market, with 185.8 billion transactions in 2023, representing 24.0% of all electronic payments in the region.

Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually

Retrieved on: 
Monday, April 29, 2024
Technology, Insurance, Health Technology, Professional Services, Cardiology, Health Insurance, Software, General Health, Health, Artificial Intelligence, Use, Radiation, University, Part, Telehealth, Diagnosis, AUC, Hospital, SPECT, Care, Cardiovascular disease, Prevalence, Molina Healthcare, Methylation, American Medical Association, Death, DNA methylation, MD, Doctor of Philosophy, CHD, Advances in Therapy, DNA, Algorithm, Patient, Moyamoya disease, CPT, PLA, Medicare, Biomarker, Intermountain Health, Associate, Medicine, VBC, Economics, CCTA, Journal, American Heart Association

PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable CHD.

Key Points: 
  • PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable CHD.
  • The model considered factors such as the number of tests performed, the cost of each test, and the impact of test results on treatment decisions.
  • The results suggest that using PrecisionCHD could lead to significant cost savings for payers, with an estimated $113.6 million saved per year for a plan with one million members.
  • These tools support targeted, data-driven decisions in CHD treatment and management, potentially revolutionizing approaches to healthcare delivery and cost management.

Cushman & Wakefield Reports Financial Results for the First Quarter 2024

Retrieved on: 
Monday, April 29, 2024
Other Construction & Property, Commercial Building & Real Estate, Construction & Property, Use, Net, GAAP, Samsung Galaxy Note 9, Uncertainty, Conference, Webcast, Employment, Financial statement, Environment, Tax, Income tax, Workforce, Credit, Growth, Note

(5) In order to assist our investors and improve comparability of results, we present the period-over-period changes in certain of our non-GAAP financial measures, such as Adjusted EBITDA, in “local” currency.

Key Points: 
  • (5) In order to assist our investors and improve comparability of results, we present the period-over-period changes in certain of our non-GAAP financial measures, such as Adjusted EBITDA, in “local” currency.
  • The local currency change represents the period-over-period change assuming no movement in foreign exchange rates from the prior period.
  • Provision for income taxes for the first quarter of 2024 was $2.3 million on a loss before income taxes of $26.5 million.
  • The Company’s First Quarter 2024 Earnings Conference Call will be held today, April 29, 2024, at 5:00 p.m. Eastern Time.

CB Financial Services, Inc. Announces First Quarter 2024 Financial Results and Declares Quarterly Cash Dividend

Retrieved on: 
Friday, April 26, 2024
Banking, Professional Services, Finance, Use, Sale, FTE, FHLB, Treasury, Death, Interest, Insurance, ACL, Newsweek, Comparison, Environment, NIM, Pressure, Bank, EPS, Advertising, FDIC, GAAP

(Comparisons to three months ended March 31, 2023 unless otherwise noted)

Key Points: 
  • (Comparisons to three months ended March 31, 2023 unless otherwise noted)
    Net income was $4.20 million, compared to $4.16 million.
  • Nonperforming loans to total loans was 0.20% at March 31, 2024 and December 31, 2023.
  • Stockholders’ equity increased $1.8 million, or 1.3%, to $141.6 million at March 31, 2024, compared to $139.8 million at December 31, 2023.
  • Book value per common share was $27.53 at March 31, 2024 compared to $27.32 at December 31, 2023, an increase of $0.21.

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

Retrieved on: 
Wednesday, April 10, 2024
Use, BioLite, Ophthalmology, Polysaccharide, Pancreatic cancer, License, Dietary supplement, Partnership, IND, CNS, Non-small-cell lung cancer, CDMO, Knowledge, Investigational New Drug, Therapy, Royalty payment, Field, Edible, Myelodysplastic syndrome, Triple-negative breast cancer, MDS, Ergosterol, NSCLC, TNBC, US FDA, Pharmaceutical industry

The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.

Key Points: 
  • The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.
  • [1]
    "We are thrilled to announce that the term sheet for a potential groundbreaking licensing deal with OncoX has been successfully executed.
  • This licensing deal marks a significant milestone for ABVC and OncoX, affirming their commitment to excellence and shared vision for the future.
  • ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707

Nature Publication Highlights the Benefits of Tropis® Intradermal When Used to Administer a First-in-Class Self-Amplifying mRNA Vaccine

Retrieved on: 
Wednesday, April 24, 2024
Health, Genetics, COVID-19, Clinical Trials, General Health, Pharmaceutical, Use, Nature, WHO, Safety, Vaccine, Therapy, Dermis, Omicron, Macrophage, Caregiver, Multimedia, Messenger, Immune system, ID, Clinical trial, B cell, Injection

Furthermore, the publication cited that the self-amplifying, thermostable mRNA platform delivered intradermally with Tropis provides a framework for next-generation vaccines that can improve accessibility and global equity.

Key Points: 
  • Furthermore, the publication cited that the self-amplifying, thermostable mRNA platform delivered intradermally with Tropis provides a framework for next-generation vaccines that can improve accessibility and global equity.
  • View the full release here: https://www.businesswire.com/news/home/20240424868674/en/
    The PharmaJet pioneering technology unlocks the rich potential of the human dermis, paving the way for enhanced immune responses.
  • Vaccine delivery directly into the dermis enables access to the immune system, with benefits on durability and breadth of immune response, and mucosal immunity.
  • PharmaJet has over 80 global development partners and Tropis has been used to perform over 10 million vaccinations in several countries.

ServiceNow Reports First Quarter 2024 Financial Results

Retrieved on: 
Wednesday, April 24, 2024
Data Management, Apps, Applications, Technology, Software, Artificial Intelligence, Internet, USD, Use, Table, Public sector, ServiceNow, Net, Security (finance), Conference, Webcast, Weakness, RPO, Privacy, Loss, Government, GAAP, Organization, Interest, Bank

The conference call will begin at 2 p.m. Pacific Time (“PT”) (21:00 GMT) on April 24, 2024.

Key Points: 
  • The conference call will begin at 2 p.m. Pacific Time (“PT”) (21:00 GMT) on April 24, 2024.
  • ServiceNow will host its Financial Analyst Day 2024 on Monday, May 6, 2024 at 1:30 p.m. PT in Las Vegas.
  • ServiceNow Chief Financial Officer Gina Mastantuono will participate in a fireside chat at the Jefferies Software Conference on Wednesday, May 29, 2024, at 11:00 a.m. PT.
  • We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current financial quarter.

LatticeFlow AI Joins the U.S. AI Safety Institute Consortium

Retrieved on: 
Tuesday, April 23, 2024
Technology, Security, Public Policy, Government, Professional Services, Software, White House, Federal Government, Data Analytics, Data Management, Artificial Intelligence, Use, Safety, Working Group, Aircraft, KPMG, Migros Bank, Nature, Risk, RMF, Trust (social science), European Parliament, House, Artificial intelligence, NYU, Business, Privacy, Consortium, Risk management, SVP, AI safety, BMW, Banking in Switzerland, NIST, Trustworthy AI, International Organization (journal), Safe, Organization, ETH, Medical device

LatticeFlow AI , the leading platform empowering Artificial Intelligence (AI) teams to build performant, safe, and trustworthy AI solutions, proudly announces that it has joined the U.S. AI Safety Institute Consortium (AISIC).

Key Points: 
  • LatticeFlow AI , the leading platform empowering Artificial Intelligence (AI) teams to build performant, safe, and trustworthy AI solutions, proudly announces that it has joined the U.S. AI Safety Institute Consortium (AISIC).
  • Dave Henry , SVP of Business Development at LatticeFlow AI, added: “AI safety programs are interdisciplinary in nature, requiring a broad range of management and technical skills to execute.
  • LatticeFlow AI’s Commitment to the U.S. and NIST’s AI Safety Institute Consortium
    With its contributions to AISIC, LatticeFlow AI will continue its commitment to helping U.S. government agencies such as the U.S. Army ensure the safety and trustworthiness of mission-critical AI systems.
  • - If you are interested in conducting an AI assessment, book a meeting with a LatticeFlow AI expert.